Trumenba (meningococcal Group B vaccine) now available in Canada

Pfizer

6 March 2018 - Trumenba is the only vaccine indicated for adolescents and young adults aged 18 to 25 to prevent meningitis B.

Pfizer Canada has announced the availability of Trumenba (meningococcal group B vaccine) in Canada, following approval by Health Canada in October 2017. Trumenba is a vaccine indicated to help prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B bacteria, for individuals 10 through 25 years of age.

Trumenba received Health Canada approval on October 5, 2017. To date, Pfizer Inc. has distributed over 1 million doses of the vaccine worldwide.

Read Pfizer press release 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Market access , Canada , Vaccine